Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 7:51 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2689–2712 of 4,249 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Study Product Clear all

Conditions: Pancreatic Cancer, Pancreatic Cancer Metastatic, PDAC, PDAC - Pancreatic Ductal Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma, Pancreatic Adenosquamous Carcinoma
Interventions: Zoldonrasib, Placebo, Oxaliplatin, Leucovorin (Calcium Folinate), 5-Fluorouracil, Irinotecan, Gemcitabine (GEM), Nab-paclitaxel; Drug
Lead sponsor: Revolution Medicines, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 670 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 18
States / cities: Phoenix, Arizona • Tucson, Arizona • New Haven, Connecticut + 14 more

Conditions: Salt; Excess, Blood Pressure Disorders
Interventions: Allopurinol, Dietary Intervention; Drug · Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 22 Years to 33 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Healthy Volunteers
Interventions: Q203, Placebo; Drug
Lead sponsor: Qurient Co., Ltd.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Adult Male, Healthy Adult Females, Joint Discomfort
Interventions: Olive Oil Extract, Placebo; Dietary Supplement
Lead sponsor: Applied Food Sciences Inc.; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 168 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Community-acquired Pneumonia
Interventions: Heparin; Drug
Lead sponsor: University of Manitoba; Other
Eligibility: 18 Years and older
Enrollment: 4,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2029
U.S. locations: 6
States / cities: Chicago, Illinois • Jefferson, Louisiana • Portland, Maine + 3 more

Conditions: Dry Eye Syndromes, Keratoconjunctivitis Sicca
Interventions: KPI-121, Placebo; Drug
Lead sponsor: Kala Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 11
States / cities: Artesia, California • Mission Hills, California • Rancho Cordova, California + 8 more

Conditions: Hematopoietic Stem Cells
Interventions: Vedolizumab Placebo, Vedolizumab; Drug
Lead sponsor: Millennium Pharmaceuticals, Inc.; Industry
Eligibility: 12 Years and older
Enrollment: 343 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 27
States / cities: Birmingham, Alabama • Los Angeles, California • Atlanta, Georgia + 18 more

Conditions: Antioxidant Absorption
Interventions: Obicetrapib 10mg, Placebo; Drug
Lead sponsor: NewAmsterdam Pharma; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Miami Gardens, Florida

Conditions: Shigellosis
Interventions: Shigella 4V, MenACWY, Rabies, Diphtheria, Tetanus and Pertussis (DTaP), Placebo; Biological
Lead sponsor: LimmaTech Biologics AG; Industry
Eligibility: 8 Months to 50 Years
Enrollment: 597 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2022
U.S. locations: 0
States / cities: Not listed

Conditions: Respiration, Artificial, Postoperative Pain, Postoperative Complications
Interventions: Intermittent Dosing of Medication; Other
Lead sponsor: Abington Memorial Hospital; Other
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Abington, Pennsylvania

Conditions: Stimulant Use Disorder
Interventions: Smartphone digital therapeutic system; Device
Lead sponsor: DynamiCare Health; Industry
Eligibility: 18 Years and older
Enrollment: 270 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Overweight and Obesity, Type2 Diabetes, NAFLD
Interventions: DD01, Placebo; Drug
Lead sponsor: Neuraly, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 255 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 3
States / cities: Chula Vista, California • Fort Myers, Florida • Orlando, Florida

Conditions: Surgical Site Infection
Interventions: Cefazolin, Water for injection; Drug
Lead sponsor: Monash University; Other
Eligibility: 18 Years and older
Enrollment: 9,180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Adenocarcinoma, Adenocystic Carcinoma, Anal Cancer, Appendix Cancer, Brain Tumor, Glioblastoma, Astrocytoma, Bile Duct Cancer, Cholangiocarcinoma, Bladder Cancer, Bone Cancer, Synovial Sarcoma, Chondrosarcoma, Liposarcoma, Sarcoma, Kaposi, Sarcoma,Soft Tissue, Sarcoma, Osteosarcoma, CNS Cancer, Brain Stem Neoplasms, Breast Cancer, Cervical Cancer, Colorectal Cancer, Rectal Cancer, Colon Cancer, Esophageal Cancer, Esophagus Cancer, Cancer of Colon, Pancreatic Cancer, Cancer of Pancreas, Testis Cancer, Testicular Cancer, Ureter Cancer, Renal Cell Carcinoma, Kidney Cancer, Gestational Trophoblastic Tumor, Head and Neck Neoplasms, Parotid Tumor, Larynx Cancer, Tongue Cancer, Pharynx Cancer, Salivary Gland Cancer, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Multiple Myeloma, Non Hodgkin Lymphoma, Carcinoid Tumor, Lung Cancer, Neuroendocrine Tumors, Mesothelioma, Thyroid Cancer, Parathyroid Neoplasms, Adrenal Cancer, Small Bowel Cancer, Stomach Cancer, Liver Cancer, Hepatic Cancer, Melanoma, Skin Cancer, Unknown Primary Tumors, Uterine Cancer, Fallopian Tube Cancer, Ovarian Cancer, Prostate Cancer, Vaginal Cancer, Penile Cancer, Vulvar Cancer, Waldenstrom Macroglobulinemia, Cancer, Advanced, Thymus Cancer, Nasopharyngeal Carcinoma, Multiple Endocrine Neoplasia, Pheochromocytoma, Small Cell Carcinoma, Pulmonary Carcinoma
Interventions: Biomarker Testing (L), Systemic Treatment (T), Patient Reported Outcomes (P); Diagnostic Test · Drug · Other
Lead sponsor: Taproot Health; Industry
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Idaho Falls, Idaho • Laredo, Texas

Conditions: Single-ventricle
Interventions: Spironolactone; Drug
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 1 Year to 6 Years
Enrollment: 98 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Osteoarthritis, Knee
Interventions: UBX0101, Placebo; Drug · Other
Lead sponsor: Unity Biotechnology, Inc.; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 20
States / cities: Birmingham, Alabama • Mobile, Alabama • Tempe, Arizona + 17 more

Conditions: Stress Urinary Incontinence
Interventions: AMDC-USR (iltamiocel), Placebo; Biological · Other
Lead sponsor: Cook MyoSite; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 20
States / cities: Tucson, Arizona • La Mesa, California • Los Angeles, California + 17 more

Conditions: Electronic Cigarette Use
Interventions: Tobacco product administration and assessment, own brand cigarettes, Tobacco product administration and assessment, ECIG 30 Watts, 0 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 8 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 15 mg/ml nicotine, Tobacco product administration and assessment, ECIG 30 Watts, 30 mg/ml nicotine; Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Postherpetic Neuralgia
Interventions: SLC022, Placebo; Drug
Lead sponsor: Solace Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 204 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 19
States / cities: Sierra Vista, Arizona • Mission Viejo, California • Orlando, Florida + 16 more

Conditions: Arthritis, Psoriatic
Interventions: Sonelokimab, Placebo; Drug
Lead sponsor: MoonLake Immunotherapeutics AG; Industry
Eligibility: 18 Years and older
Enrollment: 960 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 28
States / cities: Avondale, Arizona • Chandler, Arizona • Flagstaff, Arizona + 25 more

Conditions: HIV Infections, Lipodystrophy, Wasting Disease
Interventions: Abacavir sulfate, Atazanavir/Ritonavir, Lopinavir/Ritonavir, Nevirapine; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 13 Years and older
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2005
U.S. locations: 25
States / cities: Los Angeles, California • Torrance, California • Aurora, Colorado + 15 more

Conditions: Tobacco Use Disorder, Smoking
Interventions: Ariva Silver Wintergreen, Placebo Wintergreen; Other
Lead sponsor: Star Scientific, Inc; Industry
Eligibility: 23 Years to 72 Years
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Martinsburg, West Virginia

Conditions: Congenital Heart Disease in Children
Interventions: Continuous ketorolac; Drug
Lead sponsor: Phoenix Children's Hospital; Other
Eligibility: 3 Months to 59 Months
Enrollment: 166 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Phoenix, Arizona

Conditions: Giant Cell Arteritis
Interventions: Sirukumab, Placebo to match sirukumab, Prednisone, Placebo to match prednisone; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 161 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 13
States / cities: Aurora, Colorado • Boca Raton, Florida • Naples, Florida + 9 more

Search by objective public record fields.

Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

Uric Acid, Klotho and Salt Sensitivity in Young Adults Born Preterm

A Dose-Escalation Study to Evaluate Safety, Tolerability and Pharmacokinetics of Single Doses of Q203 in Normal, Healthy, Male and Female Volunteers

Examining Olive Oil Extract on Knee Comfort and Function

AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia

Safety and Efficacy of KPI-121 in Subjects With Dry Eye Disease

Vedolizumab in the Prophylaxis of Intestinal Acute Graft Versus Host Disease (aGVHD) in Participants Undergoing Allogeneic Hematopoietic Stem Cell (Allo-HSCT) Transplantation

Evaluation of Obicetrapib on Antioxidant Levels in Plasma and HDL Particles of Healthy Volunteers

A Study to Determine If a New Shigella Vaccine is Safe, Induces Immunity and The Best Dose Among Kenyan Infants

Sedation Administration Timing: Intermittent Dosing Reduces Time to Extubation

Smartphone Services for Stimulant Use Disorder

A Phase 1 Study of DD01 in Overweight/Obese Subjects With T2DM and NAFLD

Duration of Cardiac Antimicrobial Prophylaxis Outcomes Study

The Registry of Oncology Outcomes Associated With Testing and Treatment

Fibrosis and the Fontan

A Study to Assess the Safety and Efficacy of a Single Dose of UBX0101 in Patients With Osteoarthritis of the Knee

Autologous Muscle Derived Cells Compared to Placebo for Urinary Sphincter Repair in Post-surgical Female Stress Incontinence

Effects of E-Cigarette Nicotine Content in Smokers (Nicotine Flux Study)

Efficacy and Safety Study of SLC022 in Treating Pain Associated With Post Herpetic Neuralgia

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug

Effects of Treatment Changes on Fat Wasting in the Arms and Legs of HIV Patients

A Pilot Study to Evaluate the Efficacy of Ariva® Silver Wintergreen, a Smoking Aversive Lozenge

Continuous vs Intermittent Ketorolac for Pain Control in Peds CV Surgery

Efficacy and Safety Study of Sirukumab in Patients With Giant Cell Arteritis